GGrantIndex
← Leaderboards

Henry Richard Kranzler

Philadelphia Va Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$26,719,773
Attributed
$42,065,660
Total exposure
51
Grants
29
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$51,443,923 · 50
VA$0 · 2

By mechanism

R01$32,162,790 · 8
P30$12,186,469 · 2
P50$1,932,114 · 2
K24$1,468,908 · 1
P60$1,248,017 · 1
M01$1,027,161 · 33

Top collaborators

Most similar at Philadelphia Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectPlacebosAlcoholism /Alcohol AbuseNaltrexoneHuman Therapy EvaluationGeneticPharmaceutical PreparationsGenesAlcoholism /Alcohol Abuse ChemotherapyClinical TrialsPharmacogeneticsVariantBaseResearch PersonnelAffectResponseSamplingAlcohol DependenceUniversitiesAlcoholsFundingHeavy DrinkingResources

Grant awards (161)

Leveraging GWAS Findings to Map Variants and Identify Novel Effector Genes for Alcohol-Related Traits$624,567
R01 · FY2025 · AA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2025 · VA · contact PI
Leveraging GWAS Findings to Map Variants and Identify Novel Effector Genes for Alcohol-Related Traits$624,067
R01 · FY2024 · AA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2024 · VA · contact PI
Penn PET Addiction Center of Excellence (Penn PACE)$1,818,556
P30 · FY2023 · DA
Leveraging GWAS Findings to Map Variants and Identify Novel Effector Genes for Alcohol-Related Traits$646,254
R01 · FY2023 · AA · contact PI
Clinical Core$579,341
P30 · FY2023 · DA · contact PI
Penn PET Addiction Center of Excellence (PACE)$405,997
P30 · FY2023 · DA
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2023 · VA
Penn PET Addiction Center of Excellence (Penn PACE)$1,843,247
P30 · FY2022 · DA
Clinical Core$606,859
P30 · FY2022 · DA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2022 · VA
Penn PET Addiction Center of Excellence (Penn PACE)$1,846,343
P30 · FY2021 · DA
Clinical Core$369,269
P30 · FY2021 · DA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2021 · VA
Penn PET Addiction Center of Excellence (Penn PACE)$1,701,466
P30 · FY2020 · DA
Clinical Core$766,360
P30 · FY2020 · DA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2020 · VA
Penn PET Addiction Center of Excellence (Penn PACE)$1,762,654
P30 · FY2019 · DA
Clinical Core$486,377
P30 · FY2019 · DA · contact PI
Placebo-controlled trial of bupropion for smoking cessation in pregnant women$594,991
R01 · FY2018 · CA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$470,059
R01 · FY2018 · AA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$32,200
R01 · FY2018 · AA · contact PI
Placebo-controlled trial of bupropion for smoking cessation in pregnant women$627,587
R01 · FY2017 · CA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$520,141
R01 · FY2017 · AA · contact PI
Genetic Vulnerability for Sustained Multi-Substance Use in MVP$0
I01 · FY2017 · VA
Placebo-controlled trial of bupropion for smoking cessation in pregnant women$638,142
R01 · FY2016 · CA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$524,341
R01 · FY2016 · AA · contact PI
2/2 Pharmacogenetic Treatment for Alcoholism$422,256
R01 · FY2016 · AA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$141,916
R01 · FY2016 · AA · contact PI
Placebo-controlled trial of bupropion for smoking cessation in pregnant women$658,764
R01 · FY2015 · CA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$492,388
R01 · FY2015 · AA · contact PI
2/2 Pharmacogenetic Treatment for Alcoholism$417,530
R01 · FY2015 · AA · contact PI
Deep sequencing studies for cannabis and stimulant dependence$3,178,807
R01 · FY2014 · DA
Placebo-controlled trial of bupropion for smoking cessation in pregnant women$693,298
R01 · FY2014 · CA · contact PI
Pharmacogenetic Analysis of Topiramate Treatment of AUD$539,774
R01 · FY2014 · AA · contact PI
2/2 Pharmacogenetic Treatment for Alcoholism$425,235
R01 · FY2014 · AA · contact PI
Deep sequencing studies for cannabis and stimulant dependence$7,236
R01 · FY2014 · DA
Deep sequencing studies for cannabis and stimulant dependence$3,150,292
R01 · FY2013 · DA
2/2 Pharmacogenetic Treatment for Alcoholism$417,578
R01 · FY2013 · AA · contact PI
Deep sequencing studies for cannabis and stimulant dependence$3,385,844
R01 · FY2012 · DA
2/2 Pharmacogenetic Treatment for Alcoholism$456,310
R01 · FY2012 · AA · contact PI
Component V: Topiramante Treatment of Problem Drinkers$245,413
P60 · FY2012 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$177,021
K24 · FY2012 · AA · contact PI
Deep sequencing studies for cannabis and stimulant dependence$3,493,753
R01 · FY2011 · DA
Component V: Topiramante Treatment of Problem Drinkers$243,973
P60 · FY2011 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$176,639
K24 · FY2011 · AA · contact PI
Deep sequencing studies for cannabis and stimulant dependence$3,311,492
R01 · FY2010 · DA
Genetics of Cocaine Dependence$327,400
R01 · FY2010 · DA · contact PI
Component V: Topiramante Treatment of Problem Drinkers$255,247
P60 · FY2010 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$107,706
K24 · FY2010 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$65,426
K24 · FY2010 · AA · contact PI
Genetics of Cocaine Dependence$790,423
R01 · FY2009 · DA · contact PI
Component V: Topiramante Treatment of Problem Drinkers$267,606
P60 · FY2009 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$168,171
K24 · FY2009 · AA · contact PI
Genetics of Cocaine Dependence$781,137
R01 · FY2008 · DA · contact PI
Component V: Topiramante Treatment of Problem Drinkers$235,778
P60 · FY2008 · AA · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$95,177
K24 · FY2008 · AA · contact PI
GENETICS OF COCAINE DEPENDENCE$52,397
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SERTRALINE PHARMACOTHERAPY$37,660
M01 · FY2008 · RR · contact PI
GENETICS OF OPIOID DEPENDENCE$32,953
M01 · FY2008 · RR · contact PI
TARGETED NALTREXONE FOR PROBLEM DRINKERS$22,310
M01 · FY2008 · RR · contact PI
GENETICS OF ALCOHOL DEPENDENCE$614
M01 · FY2008 · RR · contact PI
Genetics of Cocaine Dependence$766,884
R01 · FY2007 · DA · contact PI
Sertraline Pharmacotherapy for Alcoholism Subtypes$256,591
R01 · FY2007 · AA · contact PI
Targeted naltrexone for early problem drinkers$215,901
P50 · FY2007 · AA · contact PI
TARGETED NALTREXONE FOR PROBLEM DRINKERS$46,897
M01 · FY2007 · RR · contact PI
SERTRALINE PHARMACOTHERAPY$29,958
M01 · FY2007 · RR · contact PI
GENETICS OF ALCOHOL DEPENDENCE$22,272
M01 · FY2007 · RR · contact PI
GENETICS OF COCAINE DEPENDENCE$14,901
M01 · FY2007 · RR · contact PI
GENETICS OF OPIOID DEPENDENCE$13,489
M01 · FY2007 · RR · contact PI
EFFECTS OF ARIPIPRAZOLE ON SUBJECTIVE AND PHYSIOLOGICAL RESPONSES TO ALCOHOL$6,117
M01 · FY2007 · RR · contact PI
Genetics of Cocaine Dependence$844,939
R01 · FY2006 · DA · contact PI
Sertraline Pharmacotherapy for Alcoholism Subtypes$285,320
R01 · FY2006 · AA · contact PI
Targeted naltrexone for early problem drinkers$254,279
P50 · FY2006 · AA · contact PI
PLANNING FOR A CTSA APPLICATION AT THE UNIVERSITY OF CONNECTICUT$220,850
P20 · FY2006 · RR · contact PI
Novel Approaches to Alcoholism Pharmacotherapy and Risk$135,778
K24 · FY2006 · AA · contact PI
GENETICS OF ALCOHOL DEPENDENCE$60,415
M01 · FY2006 · RR · contact PI
TARGETED NALTREXONE FOR PROBLEM DRINKERS$60,415
M01 · FY2006 · RR · contact PI
SERTRALINE PHARMACOTHERAPY$45,383
M01 · FY2006 · RR · contact PI
GENETICS OF OPIOID DEPENDENCE$19,946
M01 · FY2006 · RR · contact PI
MEMANTINE FOR ALCOHOL DEPENDENCE: AN OPEN-LABEL PILOT STUDY$12,141
M01 · FY2006 · RR · contact PI
GENETICS OF COCAINE DEPENDENCE$3,758
M01 · FY2006 · RR · contact PI
Sertraline Pharmacotherapy for Alcoholism Subtypes$492,928
R01 · FY2005 · AA
Targeted naltrexone for early problem drinkers$248,919
P50 · FY2005 · AA
Novel Approaches to Alcoholism Pharmacotherapy and Risk$135,778
K24 · FY2005 · AA
TARGETED NALTREXONE FOR PROBLEM DRINKERS$90,073
M01 · FY2005 · RR
GENETICS OF ALCOHOL DEPENDENCE$84,152
M01 · FY2005 · RR
SERTRALINE PHARMACOTHERAPY$77,295
M01 · FY2005 · RR
GENETICS OF COCAINE DEPENDENCE$10,909
M01 · FY2005 · RR
GENETICS OF OPIOID DEPENDENCE$7,480
M01 · FY2005 · RR
MEMANTINE FOR ALCOHOL DEPENDENCE: AN OPEN-LABEL PILOT STUDY$3,429
M01 · FY2005 · RR
Sertraline Pharmacotherapy for Alcoholism Subtypes$477,692
R01 · FY2004 · AA
Targeted naltrexone for early problem drinkers$240,249
P50 · FY2004 · AA
Novel Approaches to Alcoholism Pharmacotherapy and Risk$135,778
K24 · FY2004 · AA
Genetics of Alcohol Dependence$36,105
M01 · FY2004 · RR
Targeted Naltrexone for Problem Drinkers$32,858
M01 · FY2004 · RR
Genetics of Cocaine Dependence$15,091
M01 · FY2004 · RR
Finasteride$14,137
M01 · FY2004 · RR
Genetics of Opioid Dependence$9,360
M01 · FY2004 · RR
Genetic Vulnerability of Cocaine Associated Psychosis$7,833
M01 · FY2004 · RR
Molecular Genetics and Drug Dependence$5,731
M01 · FY2004 · RR
Sertraline Pharmacotherapy$1,337
M01 · FY2004 · RR
Naltrexone Injections$191
M01 · FY2004 · RR
SCIENTIFIC REVIEW AND EVALUATION AWARD$650,000
U09 · FY2003 · AA
Sertraline Pharmacotherapy for Alcoholism Subtypes$458,932
R01 · FY2003 · AA
Targeted naltrexone for early problem drinkers$234,538
P50 · FY2003 · AA
Novel Approaches to Alcoholism Pharmacotherapy and Risk$135,778
K24 · FY2003 · AA
SCIENTIFIC REVIEW AND EVALUATION AWARD$360,000
U09 · FY2002 · AA
Novel Approaches to Alcoholism Pharmacotherapy and Risk$135,656
K24 · FY2002 · AA
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$0
P50 · FY2002 · AA
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$0
M01 · FY2002 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$0
M01 · FY2002 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$0
M01 · FY2002 · RR
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$0
M01 · FY2002 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$0
M01 · FY2002 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$0
M01 · FY2002 · RR
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$184,557
P50 · FY2001 · AA
NEW APPROACHES TO THE PHARMACOTHERAPY OF ALCOHOLISM$93,807
K02 · FY2001 · AA
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$4,361
M01 · FY2001 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$4,361
M01 · FY2001 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$4,361
M01 · FY2001 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$4,361
M01 · FY2001 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$4,361
M01 · FY2001 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$4,361
M01 · FY2001 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$0
M01 · FY2001 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$0
M01 · FY2001 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$0
M01 · FY2001 · RR
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$0
P50 · FY2001 · AA
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$0
M01 · FY2001 · RR
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$0
M01 · FY2001 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$0
M01 · FY2001 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$0
M01 · FY2001 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$0
M01 · FY2001 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$0
M01 · FY2001 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$0
M01 · FY2001 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$0
M01 · FY2001 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$0
M01 · FY2001 · RR
TARGETED NALTREXONE FOR EARLY PROBLEM DRINKERS$185,722
R01 · FY2000 · AA
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$184,557
P50 · FY2000 · AA
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$184,557
P50 · FY2000 · AA
ORAL VERSUS DEPOT NALTREXONE FOR RELAPSE PREVENTION$184,557
P50 · FY2000 · AA
NEW APPROACHES TO THE PHARMACOTHERAPY OF ALCOHOLISM$93,807
K02 · FY2000 · AA
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$19,111
M01 · FY2000 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$19,111
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$19,111
M01 · FY2000 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$19,111
M01 · FY2000 · RR
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$19,111
M01 · FY2000 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$19,111
M01 · FY2000 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$4,361
M01 · FY2000 · RR
NEFAZODONE, NALTREXONE AND PLACEBO WITH RELAPSE PREVENTION OF ALCOHOLISM$4,361
M01 · FY2000 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$0
M01 · FY2000 · RR
LONG ACTING DEPOT FORMULATION OF NALTREXONE FOR ALCOHOL DEPENDENCE$0
M01 · FY2000 · RR
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$0
M01 · FY2000 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$0
M01 · FY2000 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$0
M01 · FY2000 · RR
ASSOCIATION OF DRD3 ALLELES AND COCAINE USE$0
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$0
M01 · FY2000 · RR
EFFECT OF TRYPTOPHAN DEPLETION ON MOOD AND CRAVING IN PATIENTS WITH DEPRESSION$0
M01 · FY2000 · RR
GENETIC STUDIES OF NALTREXONE RESPONSE IN ALCOHOLICS$0
M01 · FY2000 · RR
OPIOID NEUROTRANSMISSION AND RISK OF ALCOHOLISM$0
M01 · FY2000 · RR